Form 4: Amarin CFO's Equity Awards & Vesting

Amarin's SVP and CFO, Peter L. Fishman, reported recent equity transactions including RSU vestings, tax-related share dispositions, and new grants of RSUs and stock options.

Summary

• SVP and CFO Peter L. Fishman reported transactions related to his beneficial ownership in Amarin Corp PLC.
• On January 31, 2026, Fishman acquired 563 American Depositary Shares (ADSs) from the vesting of Restricted Stock Units (RSUs) granted on February 1, 2023.
• On the same date, he disposed of 310 ADSs at $15.42 to cover tax liabilities related to the RSU vesting.
• Also on January 31, 2026, Fishman acquired an additional 1,833 ADSs from the vesting of RSUs granted on February 1, 2024.
• He disposed of 1,008 ADSs at $15.42 for tax withholding purposes related to this second RSU vesting.
• On February 1, 2026, Fishman was granted 6,167 new RSUs under the Amarin Corporation plc 2011 Stock Incentive Plan.
• Additionally, on February 1, 2026, he was granted an option to purchase 27,750 ADSs at an exercise price of $14.99 per ADS.
• All reported amounts reflect an ADS ratio change effective April 11, 2025, where one ADS represents twenty Ordinary Shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects ongoing executive compensation and incentive alignment through new equity grants, which is a standard practice for retaining key management. The tax-related dispositions are routine and do not indicate negative sentiment.

Positives

• SVP and CFO Peter L. Fishman received new grants of 6,167 Restricted Stock Units (RSUs) and an option to purchase 27,750 American Depositary Shares (ADSs), indicating continued incentive alignment with shareholder interests.
• The vesting of previously granted RSUs resulted in the acquisition of 563 ADSs and 1,833 ADSs, increasing direct beneficial ownership before tax withholdings.
• The stock option grant has an exercise price of $14.99, which could provide future upside if the stock price appreciates above this level.

Negatives

• Peter L. Fishman disposed of a total of 1,318 American Depositary Shares (310 ADSs and 1,008 ADSs) at a price of $15.42 per ADS to cover tax liabilities incident to RSU vesting, which reduces his direct beneficial ownership.

Future Outlook

The filing details future vesting schedules for newly granted Restricted Stock Units (RSUs) and stock options. The 6,167 RSUs granted on February 1, 2026, will vest in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029. The option to purchase 27,750 ADSs granted on February 1, 2026, will vest 33% on its first anniversary and the remainder ratably over the subsequent eight calendar quarters, expiring on February 1, 2036.

Industry Context

StockSavvy.ai notes that executive equity grants, such as those reported by Amarin's CFO, are standard practice across the pharmaceutical and biotechnology industries. These grants are designed to align executive incentives with long-term shareholder value creation, particularly in companies focused on drug development and commercialization where long-term performance is critical. The specific vesting schedules and option terms reflect typical compensation structures aimed at retaining key talent and motivating performance over multi-year horizons.

Stakeholder Impact

• Shareholders: The new equity grants align the CFO's interests with long-term shareholder value. Tax-related dispositions are routine and have minimal market impact.
• Employees: The grants are part of an established incentive plan, which can positively influence employee morale and retention by demonstrating a commitment to performance-based compensation.

Next Steps

• First anniversary of the February 1, 2026 stock option grant for 33% vesting.
• Subsequent eight calendar quarters for ratable vesting of the remaining stock options.
• January 31, 2027: First vesting installment for 2026 RSU grant.
• January 31, 2028: Second vesting installment for 2026 RSU grant.
• January 31, 2029: Third vesting installment for 2026 RSU grant.

Key Dates

Recommendation

The filing details routine executive compensation activities, including RSU vestings and new equity grants. These transactions are expected and do not provide new information that would fundamentally alter the investment thesis for Amarin. While the new grants align management's interests with shareholders, the tax-related dispositions are standard and do not signal a change in sentiment. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for a 'buy' or 'sell' decision based solely on this Form 4.

Keywords

Amarin, AMRN, Form 4, Insider Trading, Equity Grant, Restricted Stock Units, Stock Options, CFO, Peter L. Fishman, Executive Compensation, Beneficial Ownership, ADS Ratio Change